Introduction {#s1}
============

Asthma is a chronic disease characterized by airway inflammation, remodeling, and airway hyperresponsiveness (AHR) ([@B1]). Around 5--10% of those with the disease have severe asthma with poorly controlled symptoms ([@B2]), and exacerbations are an acute, frequently occurring, and potentially severe manifestation of this illness ([@B3]). One of the main causes of asthma exacerbations are respiratory viruses, with the most common viruses responsible being human rhinoviruses (RV) ([@B4]).

RV are single-stranded RNA, non-enveloped viruses, which are members of the *Picornaviridae* family and encompass around 160 serotypes. These viruses are classified either by the A-B-C classification system (based on the similarity in the RNA sequences of the viral protein 1), whereas the major-minor-C classification system is based on the entry receptor used by the virus to enter the cell ([@B5]--[@B7]). Major serotypes bind to intracellular adhesion molecule 1 (ICAM-1) on the cell surface, minor serotypes use various low density lipoprotein receptors (LDLRs) ([@B6]) and RV-C was identified in 2006 and uses cadherin-related family member 3 (CDHR3) for binding and replication ([@B7]).

Bronchial epithelial cells are the principle site of RV binding and replication, and RV are recognized by pattern recognition receptors (PRRs) including toll-like receptors (TLR)2 and TLR3, and the Retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) melanoma differentiation-associated-protein 5 (MDA5) and retinoic acid-inducible gene (RIG-I) ([@B8], [@B9]). TLR and RLR activation induces interferon regulatory factor (IRF), mitogen-activated protein kinase (MAPK) and NF-κB signaling, leading to cytokine and interferon production ([@B10], [@B11]). Whilst this inflammation is typically readily resolved, RV infection can lead to an exaggerated response in people with asthma, resulting in excessive cytokine release and mucus hypersecretion that are characteristic of asthma exacerbations ([@B12]).

RV can promote the deposition of extracellular matrix (ECM) proteins, with tenascin-C (TN-C) mRNA expression enhanced in nasal cells following infection ([@B13]). TN-C is composed of four main domains: the tenascin assembly (TA) domain, epidermal growth factor (EGF)-like repeats, fibronectin type III (FNIII)-like repeats and fibrinogen globe-like (FBG-C) domain ([@B14]). It can range in size from 180 to 330 kDa, and expression is low in the healthy adult airway but is increased in the basement membrane of people with asthma ([@B15]). TN-C expression correlates with asthma severity in humans ([@B15]), AHR in mouse models of asthma is reduced in TN-C KO mice ([@B16]), and a single nucleotide polymorphism (SNP) in the structure of TN-C associates with adult bronchial asthma ([@B17]). TN-C is a key driver of chronic inflammation in a number of different pathologies \[summarized in ([@B18])\] through both FBG-C-TLR4 and FNIII-integrin interactions. This is well-established in models of rheumatoid arthritis (RA), with the FBG-C domain interacting with TLR4 receptors on the surface of synovial fibroblasts and macrophages ([@B14], [@B19]). However, despite evident roles for TN-C in asthma biology, the expression of TN-C in bronchial epithelial cells and the role of TN-C in RV-induced inflammation have not been studied.

In this study we investigated bronchial epithelial cell TN-C expression and release following RV infection, and determined the function of the protein. We observed release of TN-C upon infection, and established that purified recombinant FBG-C had the ability to induce inflammatory cytokine release in bronchial epithelial cells and macrophages. Surprisingly, a large proportion of TN-C was associated with small extracellular vesicles (sEV), which have previously been implicated in asthmatic airway inflammation, and viral challenge increased the concentration of overall sEV release. sEVs from virally stimulated cells had the ability to induce inflammatory and antiviral cytokine production in bronchial epithelial cells, whilst sEVs from control cells did not. Finally, sEV induced inflammation was determined to be independent of TN-C. Thus, this study identifies TN-C and sEVs as two novel drivers of the airway inflammation that underpins asthma pathogenesis, and therefore may be potential future therapeutic targets to help control RV-induced asthma exacerbations.

Materials and Methods {#s2}
=====================

Viral Culture
-------------

RV minor serotype 1B (RV-1B) and major serotype 16 (RV-16) were obtained from ATCC (LGC Standards, Teddington, UK) and viral stocks generated by infecting HeLa Ohio cells (ATTC) as previously described ([@B20]). The cytopathic effect was then determined and the multiplicity of infection (MOI) calculated.

Cell Culture
------------

The BEAS-2B epithelial cell line, and primary bronchial epithelial cells (PBECs) isolated from healthy humans, were purchased from ATCC and Promocell (Heidelberg, Germany) and cells were maintained as described ([@B21], [@B22]). PBECs were also obtained during bronchoscopy from adult (18--55 years old) non-atopic non-asthmatic controls (NANA) and patients with atopic asthma (AA) ([@B23]), with written informed consent, in accordance with the Declaration of Helsinki and a protocol approved by London Bridge Research Ethics committee (reference number 12/LO/1278), and maintained in the same way as the purchased cells. The AA subjects had a prior clinical diagnosis of asthma, scored \> 0.75 on an asthma control questionnaire, had a histamine PC~20~ of \<8 μg/ml, and atopy was confirmed by a positive skin prick test to timothy grass pollen (in a panel of 10 aeroallergens) ([@B23]). NANA subjects had a histamine PC~20~ of \>8 μg/ml ([@B23]). Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral venous blood of healthy volunteers ([@B21]), with written informed consent, in accordance with a protocol approved by South Sheffield Local Research Ethics Committee (reference number: 05/Q2305/4) and differentiated into monocyte-derived macrophages using a previously established method ([@B14]).

Cell Stimulation and Infection
------------------------------

Cells were seeded in 6, 12 or 96 well plates, grown to confluency (80%) and placed in supplement free media overnight. For stimulation experiments, cells were stimulated with 25 μg/ml polyinosinic:polycytidylic acid (poly(\[I:C\]) (Invitrogen, Paisley, UK), 10 μg/ml gardiquimod (Invitrogen) or 100 ng/ml or lipopolysaccharide (LPS) serotype 0111:B4 (Sigma-Aldrich) or EH100 (Enzo, Exeter, UK). For infection experiments, BEAS-2B cells or PBECs were infected with RV-1B and RV-16 (ATCC) for the indicated times at optimized MOIs ([@B10]). For TN-C stimulation experiments, recombinant FBG-C protein was expressed and purified as described ([@B14], [@B24]), before being added to cells at the indicated concentrations for 24 h. For small extracellular vesicle (sEV) stimulation experiments, isolated sEVs (see [Supplementary Methods](#SM3){ref-type="supplementary-material"}) were added to at the indicated concentrations for 24 h. Cell free supernatants, mRNA and/or protein lysates were then harvested and stored appropriately.

Murine Model
------------

This study was carried out in accordance with the principles of the Basel Declaration and recommendations of Animal (Scientific Procedures) Act 1986, United Kingdom Home Office. The protocol was approved by the animal welfare and ethical review body at the University of Sheffield, and work was carried out under project license code 40/3726 and establishment license code 50/2509. Under 4% isofluorane (Abbott Laboratories Illinois, USA), C57BL/6 adult mice (see [Supplementary Methods](#SM3){ref-type="supplementary-material"} for more information) were intranasally stimulated with 50 μl PBS (Oxoid, ThermoFisher, Basingstoke, UK) or 50 μl PBS containing 100 μg poly(I:C). The mice were sacrificed and bronchoalveolar lavage fluid (BALF) collected as previously described ([@B25]).

Western Blot
------------

Where required, cell lysates were prepared as previously established ([@B21]). For supernatant samples, 4 × SDS loading buffer was added and samples were analyzed following the same protocol. Cell-lysate western blot samples were probed for human TN-C (N-Terminal, mab1908, Merck Millipore, California, USA), Histidine-Tag (H1029, Sigma-Aldrich), and β-actin (A5316, Sigma-Aldrich), with TN-C expression normalized to β-actin, whilst supernatant samples were analyzed for TN-C only. Mouse BALF was concentrated by trichloroacetic acid (TCA, Sigma-Aldrich) precipitation prior to analysis and TN-C expression determined using mouse TN-C antibody (N-Terminal, T3413, Sigma-Aldrich). sEV isolates were analyzed for sEV-enriched proteins cluster of differentiation 9 (CD9, sc-13118, Santa-Cruz Biotechnology, Dallas, USA) and flotillin-1 (ab13493, Abcam, Cambridge, UK), with the negative control glucose regulated protein 94 (GRP94, ab7291, Abcam) utilized to confirm the lack of cellular protein contamination. Densitometrical analysis was performed using ImageJ software (Version 1.5i; NIH). Due to multiple variants of TN-C being expressed, the dominantly expressed band was measured for each experiment.

ELISA
-----

Cell-free supernatants were collected and quantified for C-X-C Motif Ligand 8 (CXCL8), CCL5, and IL-5 (R&D, Minneapolis, USA) and TN-C N-Terminal Kit (Cloud Corp, Texas, USA) using matched Ab pairs by enzyme-linked immunosorbent assay (ELISA), following the manufacturer\'s instructions. Minimum detection levels (all pg/ml) were CXCL8: 78.125, TN-C: 125, IL-5: 156.25, and CCL5: 156.25.

MTT Assay
---------

The 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay assessed nicotinamide adenine dinucleotide phosphate (NADPH) activity as a measure of cell metabolic activity and thus viability, and was performed as previously described ([@B26]).

Nanoparticle Tracking Analysis
------------------------------

The size and concentration of the isolated EVs were analyzed by the ZetaView® Nanoparticle Tracking Analyser (Particle Metrix, Dusseldorf, Germany). Each sample was diluted in filtered PBS (1:30--1:50) to reach the optimum detection limit in the machine and measured three times.

Statistics
----------

Data were analyzed and presented via GraphPad Prism v7.0 (California, USA) as mean ± SEM of at least three independent experiments, with each replicate carried out on a separate BEAS-2B cell passage or independent PBEC donor, please see figure legends for specific experimental replicate numbers. Statistical tests performed are also detailed within the figure legends with significant differences indicated by \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001.

Results {#s3}
=======

RV Infection Induces TN-C Release *in vitro* in PBECs, With Release Greater in PBECs Obtained From People With Asthma, Whilst the Viral Mimic Poly(I:C) Induces TN-C Release Into the Murine Airway
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TN-C is a protein that, once released, can have a pro-inflammatory function upon interaction with cells such as macrophages ([@B14]). Therefore, we first investigated whether epithelial cell TN-C release occurred in response to RV. PBECs from NANA (healthy non-atopic non-asthmatic control) and AA (atopic asthmatic) adult patients were obtained and infected with RV-1B (a minor group RV) and RV-16 (a major group RV) *in vitro*. Western blotting of cell culture supernatant revealed increased TN-C release upon infection with both RV serotypes. When analyzed by densitometry and normalized to total protein concentration (determined by bicinchoninic acid assay), RV-16 infection produced greater TN-C release in AA PBECs compared to the AA media control and to the NANA RV-16 treated samples ([Figures 1A,B](#F1){ref-type="fig"}). Due to previous evidence of TN-C KO mice having reduced AHR severity ([@B16]), the relationship between poly(I:C) (a TLR3 agonist and viral mimic) stimulation and TN-C release in an *in vivo* murine model was also investigated. C57BL/6 mice were stimulated intranasally with poly(I:C), using PBS as a vehicle control, sacrificed at the indicated times, and BALF collected. Western blotting BALF revealed TN-C levels were increased 48 h post-poly(I:C) stimulation, compared to the PBS treated controls ([Figures 1C,D](#F1){ref-type="fig"}).

![RV infection induces TN-C release *in vitro* and poly(I:C) induces TN-C *in vivo*, with increased release observed in bronchial epithelial cells from people with asthma. **(A,B)** Cell-free supernatants from NANA and AA PBECs, infected with RV-1B and RV-16 for 6 or 24 h, were obtained from the ALLIANCE study. **(A)** Cell-free supernatants were analyzed by western blot using antibodies specific to TN-C (one representative blot shown), with media samples (M), RV-1B (1B), and RV-16 samples (16). **(B)** Densitometry of the large \>250 kDa variant was performed in ImageJ and normalized to protein concentration (determined by a bicinchoninic acid assay). Data shown are mean ± SEM with each replicate carried out using an independent PBEC donor (*n* = 4). **(C,D)** Under recovery anesthesia, adult C57BL/6 mice were treated intranasally with 50 μl PBS or 100 μg poly(I:C) in 50 μl PBS for up to 48 h. The mice were then sacrificed, and BALF was collected by washing the lungs with 3 ml of PBS. **(C)** 150 μl of mouse BALF was TCA precipitated to a final volume of 20 μl and the presence of TN-C at 24 and 48 h was analyzed by western blot (48 h blot shown). **(D)** Densitometry of the small \~250 kDa variant was then performed using ImageJ software and normalized to neutrophil cell count. Data shown are mean ± SEM from a single experiment, with each point a separate mouse (3 mice for PBS treatment and 7 mice for poly(I:C) treatment). Significant differences in TN-C secretion are indicated by ^\#^*p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; analyzed by two way ANOVA with Tukey\'s *post-hoc* test.](fimmu-10-01987-g0001){#F1}

TN-C Expression and Release in Bronchial Epithelial Cells Is Triggered by TLR3, but Not TLR7, Activation
--------------------------------------------------------------------------------------------------------

TN-C release in response to RV infection of human bronchial epithelial cells *in vitro* has not, to our knowledge, been previously determined. Thus, we further investigated this pathway, as well as examining the TLRs responsible. TN-C mRNA levels, and protein expression and release, in response to RV, poly(I:C) and gardiquimod (a TLR7 agonist) in the BEAS-2B cell line and PBECs from healthy donors was determined, with TNFα used as a positive control. TN-C mRNA expression was analyzed by qPCR and normalized to GAPDH expression. Cell-associated TN-C expression and TN-C release was assessed by western blotting cell lysates and cell supernatant, respectively, and normalized to β-actin (lysates only). TN-C levels in cell supernatants were further quantified by ELISA.

TN-C release in PBECs in response to RV-1B ([Figure 2A](#F2){ref-type="fig"}) and RV-16 ([Figure 2B](#F2){ref-type="fig"}) infection was confirmed by TN-C ELISA, with peak TN-C release occurring at 48--72 h post-infection. PBECs also released TN-C upon stimulation with poly(I:C) ([Figure 2C](#F2){ref-type="fig"}), and we confirmed that as expected poly(I:C) induced the release of CXCL8 ([Supplementary Figures 1A,C](#SM2){ref-type="supplementary-material"}) and CCL5 ([Supplementary Figures 1B,D](#SM2){ref-type="supplementary-material"}) from both BEAS-2B and PBECs. To confirm the specificity of the TN-C antibody, recombinant TN-C with a histidine-tag was purified and compared to PBEC intracellular associated TN-C by western blot. The purified TN-C displayed the same band pattern as the more complex cellular samples ([Supplementary Figure 1E](#SM2){ref-type="supplementary-material"}). PBECs did not respond to gardiquimod stimulation (as measured by CXCL8; [Supplementary Figure 2A](#SM2){ref-type="supplementary-material"}) and TN-C release did not occur (measured by western blot; [Supplementary Figure 2B](#SM2){ref-type="supplementary-material"}). Gardiquimod activity was confirmed by stimulation of macrophages ([Supplementary Figure 2A](#SM2){ref-type="supplementary-material"}). Poly(I:C) and RV-1B treatment of BEAS-2B cells also resulted in TN-C release ([Figure 2D](#F2){ref-type="fig"}), with no response to gardiquimod (data not shown). Together these data demonstrate TN-C release is not RV serotype specific and can be promoted by TLR3, but not TLR7 activation in primary human epithelial cells and cell lines.

![RV induced TN-C release from bronchial epithelial cells is triggered by TLR3 activation and is not RV-serotype specific. PBECs **(A--C)** and BEAS-2B cells **(D)** were treated with poly(I:C) (25 μg/ml), RV-1B (MOI 0.6), or RV-16 (MOI 1.5) for the indicated times. Cell-free supernatants were analyzed by ELISA to measure TN-C release. Data shown are mean ± SEM (*N* = 3--5) with each replicate a separate BEAS-2B cell passage or independent PBEC donor. Significant differences in TN-C release are indicated by \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; analyzed by Kruskal-Wallis one-way ANOVA with Dunn\'s *post-hoc* test **(A,C)** or two way repeated measures ANOVA with Tukey\'s *post-hoc* test **(B,D)**.](fimmu-10-01987-g0002){#F2}

Upregulation of TN-C mRNA and cell-associated TN-C protein was not observed in PBECs in response to poly(I:C), RV-1B or RV-16 (data not shown), whilst poly(I:C) stimulated TN-C mRNA expression in BEAS-2B cells at 24 h ([Supplementary Figure 2C](#SM2){ref-type="supplementary-material"}), and cell-associated TN-C protein expression at 24 and 48 h post-stimulation ([Supplementary Figure 2D](#SM2){ref-type="supplementary-material"}), with levels of expression similar to that induced by TNFα. Basal levels of TN-C mRNA expression ([Supplementary Figure 2E](#SM2){ref-type="supplementary-material"}) and cell-associated protein ([Supplementary Figure 2F](#SM2){ref-type="supplementary-material"}) were significantly greater in PBECs compared to BEAS-2B cells. Together these data show a cell-type specific effect of viral infection/poly(I:C) stimulation on TN-C expression, and suggests that the required rate of TN-C transcription needed to facilitate protein release depends on existing intracellular expression.

TN-C Release Does Not Occur as a Result of Cell Death
-----------------------------------------------------

The next aim was to investigate the mechanism of TN-C release following viral infection. RV infection of bronchial epithelial cells can promote the induction of apoptosis ([@B27]), and it was important to ascertain whether the observed TN-C release is directly promoted by infection or an indirect by-product of RV-induced cytotoxicity.

PBECs were infected with RV, stimulated with poly(I:C), or treated with staurosporine (a promoter of apoptosis) for up to 72 h, and the MTT cell metabolic activity assay performed. Supernatants were collected and TN-C levels were compared by western blot. RV infection resulted in a significant reduction in cell metabolic activity (\~30%; [Figure 3A](#F3){ref-type="fig"}) whilst staurosporine treatment caused \~70--80% reduction ([Figures 3A,B](#F3){ref-type="fig"}) compared to the media control. In contrast, poly(I:C) did not affect cell metabolic activity. Importantly, RV infection ([Figures 3C,E](#F3){ref-type="fig"}) and poly(I:C) stimulation ([Figures 3D,F](#F3){ref-type="fig"}) both induced TN-C release from PBECs, whilst staurosporine treatment did not ([Figures 3C--F](#F3){ref-type="fig"}). This indicates that virally induced TN-C release is not associated with significant changes in cell viability and that induction of epithelial cell death is not sufficient to induce TN-C release.

![Induction of epithelial cell death is not sufficient to induce PBEC TN-C release. PBECs were grown to confluence and infected with RV-1B (MOI 0.6) or stimulated with poly(I:C) (25 μg/ml) or staurosporine (5 μg/ml) for the indicated times. Metabolic activity was measured by MTT assay in response to RV and staurosporine **(A)** and poly(I:C) and staurosporine **(B)**. The presence of TN-C was analyzed by western blot (M for Media, R for RV-1B, P for poly(I:C), and S for staurosporine; one representative blot shown; **(C,D)**. Densitometry of the large \>250 kDa variant in response to RV **(E)** and poly(I:C) **(F)** was performed in ImageJ software. Values are expressed as mean ± SEM (*N* = 3--4) with each replicate representing an independent PBEC donor. Significant differences in cell viability (\# compared to media control which was assigned 100% and \* compared to poly(I:C)/RV) and TN-C release are indicated by, \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001; \#\#*p* \< 0.01; \#\#\#\#*p* \< 0.0001, analyzed by two way ANOVA with Dunnett\'s *post-hoc* test. Analysis for MTT assay was performed on raw values.](fimmu-10-01987-g0003){#F3}

Poly(I:C) Stimulation of BEAS-2B Cells Induces sEV-Associated TN-C Release
--------------------------------------------------------------------------

sEVs are a type of extracellular vesicle (EV) that range from 50 to 200 nm in size and originate from the endosomal pathway or the plasma membrane ([@B28], [@B29]). sEVs can encompass exosomes and smaller microvesicles, and were investigated as a potential mechanism of TN-C release as TN-C association with these vesicles has previously been reported in cancerous colorectal cell lines ([@B29]) and sEVs have been implicated in asthma pathogenesis and airway inflammation ([@B30]). There is a need for large amounts of sEVs to be isolated for accurate NTA analysis and sEVs also have a short storage time before degradation, thus, BEAS-2B cells were chosen as suitable cells, due to their quicker doubling time and greater density in culture than PBECs.

BEAS-2B cells were cultured in EV-depleted media, stimulated with poly(I:C) and supernatant collected for sEV isolation, using a four-step ultracentrifugation method ([Supplementary Figure 3A](#SM2){ref-type="supplementary-material"}). The sEVs were characterized by western blotting, confirming the presence of sEV enriched-proteins CD9 and flotillin-1, and the absence of intracellular protein control GRP94 in the sEV samples ([Figure 4A](#F4){ref-type="fig"}). The average sEV size, as determined by NTA, was 100 nm and the concentration of sEVs increased at 72 h post-stimulation ([Figure 4B](#F4){ref-type="fig"}). sEV associated TN-C expression was measured by western blot, and increased at 72 h post-stimulation ([Figures 4C,D](#F4){ref-type="fig"}). Analysis of the amount of TN-C left in the supernatant after sEV isolation demonstrated that \~50% of released TN-C is associated with sEVs ([Supplementary Figure 3B](#SM2){ref-type="supplementary-material"}). Together these data reveal that TN-C release occurs in two formats; soluble TN-C protein in the cell supernatant and TN-C protein associated with sEVs.

![Poly(I:C) stimulation of BEAS-2B cells induces the release of sEVs and sEV-associated TN-C expression. BEAS-2B cells were grown to confluence in EV-depleted media and stimulated with poly(I:C) (25 μg/ml) for the indicated times. sEVs were then isolated by the four spin ultracentrifugation method and re-suspended in 100 μl PBS. **(A)** CD9, flotillin-1 and GRP-94 expression was measured by western blot (one representative blot shown). **(B)** sEV concentration and size was quantified by Nanoparticle Tracking Analysis on ZetaView. **(C)** TN-C expression was measured by western blot (one representative blot shown) and **(D)** TN-C expression was quantified by densitometry using ImageJ software. Values are expressed as mean ± SEM (*N* = 7) with each replicate a different cell passage. Significant differences in sEV release and sEV-associated protein expression are indicated by \**p* \< 0.05, analyzed by Mann-Whitney *U* test **(B)** or two way ANOVA with Tukey\'s *post-hoc* test **(D)**.](fimmu-10-01987-g0004){#F4}

FBG-C and Poly(I:C)-Induced sEVs Induce Cytokine Release in BEAS-2B Cells, but the sEV-Pathway May Not be TN-C-Dependent
------------------------------------------------------------------------------------------------------------------------

This work has demonstrated that RV infection induces the release of soluble TN-C from bronchial epithelial cells, and that TN-C is also associated with poly(I:C)-induced sEV release. As the inflammatory function of TN-C on epithelial cells has not been investigated, we measured the effect of soluble FBG-C on BEAS-2B cells, using macrophages as a control cell type. RV infection has also been hypothesized to induce changes in the sEV miRNA composition, potentially contributing to enhanced airway inflammation and anti-viral activity ([@B31]), whilst sEVs from nasal lavage fluid of people with chronic airway inflammation contain altered protein cargo ([@B32]). The inflammatory and anti-viral consequence of sEV addition to BEAS-2B cells was therefore investigated, and the role of TN-C in this pathway determined.

FBG-C was purified by Ni^2+^ purification as per ([@B14], [@B24]) and characterized for activity and structure ([Supplementary Figures 4A--C](#SM2){ref-type="supplementary-material"}). A concentration response curve was generated in BEAS-2B cells, with 1--2 μM FBG-C determined to be sufficient to induce CXCL8 release ([Supplementary Figure 4D](#SM2){ref-type="supplementary-material"}). MDMs were also stimulated with 1 μM FBG-C, with previous work in our group demonstrating that concentrations between 0.05 and 1 μM were sufficient to induce an inflammatory response ([@B14], [@B24]). FBG-C was added exogenously to macrophages (with an LPS TLR4 positive control) or BEAS-2B cells, cell-free supernatants were collected, and CXCL8 release analyzed by ELISA. FBG-C stimulation resulted in substantial CXCL8 release in macrophages, with the amount released similar to that elicited by LPS stimulation ([Figure 5A](#F5){ref-type="fig"}). Due to contradictory evidence about the ability of bronchial epithelial cells to respond to LPS (and thus respond to TLR4 agonists) ([@B20]), BEAS-2B cells were first stimulated with rough LPS serotype EH100 and smooth LPS serotype 0111:B4 and CXCL8 production measured. Smooth LPS, but not rough LPS induced significant cytokine release from BEAS-2B cells ([Figure 5B](#F5){ref-type="fig"}); whilst TN-C-FBG stimulation (1 μM) also elicited CXCL8 release in BEAS-2B cells ([Figure 5C](#F5){ref-type="fig"}).

![FBG-C induces cytokine release in macrophages and BEAS-2B cells and sEVs isolated from virally-stimulated BEAS-2B cells induce BEAS-2B cell cytokine release which may be independent from TN-C. **(A)** Monocyte derived macrophages were left unstimulated or stimulated with purified recombinant FBG-C (1 μM) or LPS smooth (S) serotype 0111:B4 (10 μg/ml) for 24 h. **(B)** BEAS-2B cells were left unstimulated or stimulated with LPS smooth serotype 0111:B4 (10 μg/ml), LPS rough (R) serotype EH100 (10 μg/ml) or **(C)** FBG-C (1 μM) for 24 h. **(D--F)** BEAS-2B cells were grown to confluence in EV-depleted media, and stimulated with poly(I:C) (25 μg/ml) for 72 h. sEVs were then isolated by the four spin purification method, re-suspended in 100 μl PBS and the concentration measured by NTA. sEVs were added to fresh BEAS-2B cells at the designated concentrations and cell free supernatants were collected at 24 h. **(D)** CXCL8 (with a 0 h poly(I:C) control), **(E)** IL-6 and **(F)** CCL5 were measured by ELISA. **(G,H)** BEAS-2B cells were pre-treated with 100 nM TN-C siRNA or 100 nM control siRNA for 24 h, and then stimulated with poly(I:C) (25 μg/ml) for 72 h. sEVs were isolated by the four-step ultracentrifugation method and TN-C expression was determined by western blot. BEAS-2B cells were then stimulated with the siRNA treated sEVs for 24 h. Cell free supernatants were collected and analyzed for **(G)** CXCL8 and **(H)** CCL5 release by ELISA. Data are expressed as mean ± SEM (*N* = 3--4) with each replicate a different cell passage and separate sEV population. Significant cytokine release is indicated by \**p* \< 0.05, analyzed by Kruskal-Wallis with Dunn\'s *post-hoc* test **(A,B,G,H)**, Mann-Whitney *U* Test **(C)** or two way ANOVA with Tukey\'s *post-hoc* test **(D,E,F)**.](fimmu-10-01987-g0005){#F5}

BEAS-2B cells were next stimulated with poly(I:C) for 72 h and sEVs were isolated as per [Supplementary Figure 3A](#SM2){ref-type="supplementary-material"}. sEVs were quantified by NTA and added to BEAS-2B cells at 10,000--20,000 sEVs per μl for 24 h, before cell free supernatants were collected for analysis. Addition of unstimulated media control sEVs did not induce any cytokine release from BEAS-2B cells, whilst addition of sEVs from poly(I:C) stimulated cells induced CXCL8 ([Figure 5D](#F5){ref-type="fig"}), IL-6 ([Figure 5E](#F5){ref-type="fig"}), and CCL5 ([Figure 5F](#F5){ref-type="fig"}) release. A 0 h control was used in the CXCL8 experiment, with sEVs isolated instantly after poly(I:C) stimulation. No CXCL8 release was induced, demonstrating a lack of poly(I:C) contamination. To determine what role TN-C played in this response, the experiment was repeated with a 100 nM TN-C siRNA or 100 nM control siRNA pre-treatment step prior to poly(I:C) stimulation. Despite a knockdown efficiency of \~75% ([Supplementary Figures 4E,F](#SM2){ref-type="supplementary-material"}), there was no difference in poly(I:C) induced CXCL8 ([Figure 5G](#F5){ref-type="fig"}) or CCL5 ([Figure 5H](#F5){ref-type="fig"}) release between the two siRNA groups.

Discussion {#s4}
==========

This study identifies two novel pathways that can mediate inflammation in bronchial epithelial cells and macrophages: the release of the ECM protein TN-C in response to RV infection (which is elevated in PBECs from people from asthma), and the generation and release of sEVs in response to TLR3 stimulation by poly(I:C).

The proposed mechanisms of RV-dependent TN-C release and poly(I:C)-dependent sEV release are summarized in [Figure 6](#F6){ref-type="fig"}. Work in this study determined that TN-C release in bronchial epithelial cells is triggered by TLR3, but not TLR7 signaling, with the lack of response to gardiquimod correlating with previous work from our lab ([@B21]). TN-C release occurred in response to both minor and major RV serotypes. In contrast, intracellular TN-C was not upregulated in response to RV in PBECs, results which are in keeping with another study, which demonstrated RV infection of primary airway smooth muscle cells did not promote expression of TN-C ([@B33]). The amount of RV-dependent TN-C upregulation may depend on basal levels of expression. We theorize that the lack of significant intracellular upregulation of TN-C in PBECs following infection was due to the high basal levels that are present in the cells, and therefore promotion of TN-C expression was not required in order for the protein to be released. This also explains why upregulation was observed in BEAS-2B cells upon stimulation and infection, as these cells express low basal levels of TN-C. As TNFα and TGFβ are known transcriptional regulators of TN-C ([@B34], [@B35]), and are produced in response to RV infection ([@B36]), we postulate these cytokines trigger the signaling cascades that promote the release of TN-C from bronchial epithelial cells. This pathway was also confirmed *in vivo*, with nasal administration of poly(I:C) inducing TN-C release in BALF from mice at 48 h post-stimulation. Poly(I:C) was chosen as a relevant stimulus as this model has previously been shown to elicit lung inflammation and impair lung function in mice in a TLR3 dependent manner ([@B37]). We confirmed that poly(I:C) produced a robust immune response 48 h post-stimulation (data not shown).

![The proposed mechanism of TN-C release following RV infection of bronchial epithelial cells. Upon viral infection, RV is internalized to the early endosome and uncoats. The single stranded RNA exits the endosome (early or late endosome depending on the RV serotype) and forms a temporary double stranded RNA intermediate (recognized by TLR3 in the cytoplasm). It is not yet clear how the endosomal TLR recognizes the cytoplasmic RNA. Poly(I:C) enters the endosome upon addition to cells and stimulates the TLR3 pathway. The amount of RV/Poly(I:C)-dependent cell associated TN-C upregulation may depend on existing basal levels of expression in the cell, with PBECs expressing higher TN-C levels at baseline compared to BEAS-2B cells. Furthermore, RV-induced TN-C release occurs in response to major and minor serotypes of RV, and is not an indirect consequence of cell cytotoxicity, as poly(I:C) induces TN-C release despite no significant cell death. Activation of the TLR3 dependent pathway (and other pathways upon viral infection) induce the release of TNFα and TGFβ, known transcriptional regulators of TN-C through the MAPK/ERK and NF-κB/p65 pathways. It is postulated that this triggers the signaling cascade required for the expression and release of TN-C in PBECs. Black lines denote events determined by experiments with both poly(I:C) and RV, the dashed line indicates events that occur in RV infection and the dotted line indicates events determined by experiments with poly(I:C) only.](fimmu-10-01987-g0006){#F6}

Once released into surrounding environment, soluble TN-C has the ability to induce TLR4 inflammation through the FBG-C domain. BEAS-2B cells in culture have the ability to respond to smooth LPS but not rough LPS \[which can be overcome by co-culture with monocytes, which provide the required co-receptors ([@B20])\], and our work now reveals that FBG-C can also induce inflammatory cytokine release from bronchial epithelial cells. This draws a parallel with, and builds on, our previous work demonstrating the ability of TN-C to induce inflammatory cytokine release via FBG-C-TLR4 interactions in macrophages and fibroblasts ([@B14]). Work in the future will aim to detail exactly how much TN-C is released in the airway following infection, both from AA and NANA samples.

RV infection lasts on average 9--11 days, meaning multiple rounds of infection, viral egress, and reinfection occur ([@B38]). Evidence is contradictory about whether asthma suffers are more susceptible to RV infection, however it is clear that RV infection persists longer in people with asthma and they have more severe symptoms ([@B38]). The isoforms of TN-C released in response to RV are large (\>250 kDa), which are more resistant to matrix metalloproteinase 9 (MMP9) degradation ([@B39]) and have a greater capacity to induce inflammation than smaller isoforms ([@B14], [@B40]). In people with asthma, the exaggerated response to RV infection, leading to greater TN-C release, could lead to TN-C persisting in the airway after the clearance of viral infection, incorporating into the ECM and exerting its inflammatory effect locally ([@B15]). Furthermore, the release of TN-C could form a positive feedback loop (previously demonstrated in RA), further increasing expression and release of the protein ([@B41]). Also, viral infection itself may result in a greater susceptibility to virally induced-TN-C release and the consequential TLR4 dependent inflammation, with respiratory syncytial virus (RSV) having been previously shown to induce the upregulation of TLR4 in bronchial epithelial cells ([@B42]).

The work described here also established that poly(I:C) stimulation of BEAS-2B cells induced sEV release and provided novel information that TN-C is associated with these vesicles. Results from this study demonstrate that \~50% of the released TN-C was associated with sEVs, whilst the other 50% was present in the supernatant. This study establishes sEVs as an inflammatory pathway of importance in the airway, with initial results indicating that sEVs exert an inflammatory effect in a TN-C-independent manner. However, as 100% of TN-C knockdown was not achieved, further investigation is required in order to discount TN-C from having a role in TLR3-induced sEV-dependent inflammation. The results in this manuscript are consistent with a recent study that demonstrated that RSV-induced sEVs promote inflammatory cytokine release in an alveolar epithelial cell line through IP-10, CCL2, and CXCL10 release ([@B43]). Our work also highlights for the first time that virally-stimulated sEVs promote an anti-viral CCL5 response in surrounding bronchial epithelial cells after infection. sEVs can also "travel" quite large distances of at least several cell diameters ([@B44]), and thus will induce a more widespread immune response to RV infection than soluble TN-C.

The revelation that RV infection and poly(I:C) stimulation can induce inflammatory TN-C and/or sEV release is of importance in the context of virally-induced asthma exacerbations. TN-C release was increased in the PBECs of AA subjects in response to RV, potentially providing evidence of a mechanism for the increased expression of the protein in the basement membrane of people with asthma ([@B13], [@B15]). As detailed above, RV infections persist longer in people with asthma ([@B38]) and this, alongside increased basal cell-associated expression of TN-C in people with asthma ([@B15]), may result in the greater release of the protein upon infection, promoting a chronic inflammatory response and contributing toward the development of AHR. Furthermore, sEVs isolated from the BALF of people with asthma have an increased inflammatory miRNA profile which can contribute toward pathogenesis ([@B45]), and thus RV infection may shift the imbalance of sEV miRNA profile even further.

Now the novel mechanisms of RV-induced TN-C release and poly(I:C) induced sEV release have been established, it will be paramount in the future to further characterize these pathways. We aim to investigate whether RV induces sEVs with a similar inflammatory phenotype to poly(I:C), and whether this is potentiated further in people with asthma. TN-C is a protein that can be targeted therapeutically with monoclonal antibodies that target the TLR4 binding epitope on the FBG-C domain, reducing cytokine release in RA synovial cells ([@B19]). Thus, TN-C may be a potential therapeutic target in the future in order to reduce a local inflammatory response to TN-C following RV-dependent release. Furthermore, sEVs are currently used as biomarkers in cancers such as colorectal cancer ([@B46]), and as more work unveils the role of sEVs in asthma, these vesicles, and the levels of associated TN-C, should be considered as a potential biomarker for disease severity.

The data presented in this study reveals novel consequences of RV infection and poly(I:C) stimulation of bronchial epithelial cells: the induction of pro-inflammatory TN-C release that can activate local cytokine synthesis in the airway, and the release of sEVs (that contain TN-C) which have the ability to induce an immune response over longer distances. The pathway of TN-C release is also more active in the airway of people with asthma and thus identifies TN-C and sEVs as relevant to the biology of virally induced exacerbations of asthma.
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AA

:   Atopic Asthmatic

AHR

:   Airway Hyperresponsiveness

BALF

:   Bronchoalveolar Lavage Fluid

CD9

:   Cluster of Differentiation 9

CXCL8

:   C-X-C Motif Ligand 8

ECM

:   Extracellular Matrix Protein

ELISA

:   Enzyme-Linked Immunosorbent Assay

FNIII

:   Fibronectin Type III-Like

EGF

:   Epidermal Growth Factor-Like

EV

:   Extracellular Vesicle

FBG-C

:   Fibrinogen Globe-Like

GRP94

:   Glucose Regulated Protein 94

RV

:   Human Rhinovirus

IRF

:   Interferon Regulatory Factor

LAL

:   Limulus Amebocyte Lysate

lEV

:   Large Extracellular Vesicle

LPS

:   Lipopolysaccharide

MAPK

:   Mitogen Activated Protein Kinase

MMP9

:   Matrix Metalloproteinase 9

MDA5

:   Melanoma Differentiation-Associated Protein 5

MOI

:   Multiplicity of Infection

MTT

:   3-(4,5-Dimethylthiazol-2yl)-2,5-Diphenyltetrazolium Bromide

NADPH

:   Nicotinamide Adenine Dinucleotide Phosphate

NANA

:   Non-Atopic Non-Asthmatic

PBEC

:   Primary Bronchial Epithelial Cell

PBMC

:   Peripheral Blood Mononuclear Cell

Poly(I:C)

:   Polyinosinic:Polycytidylic Acid

RA

:   Rheumatoid Arthritis

RIG-1

:   Retinoic Acid-Inducible Gene I

RLR

:   RIG-I-Like Receptor

RSV

:   Respiratory Syncytial Virus

SNP

:   Single Nucleotide Polymorphisms

sEV

:   Small Extracellular Vesicle

TA

:   Tenascin-Assembly

TCA

:   Trichloroacetic Acid

TGFβ

:   Transforming Growth Factor beta

TLR

:   Toll-Like Receptor

TN-C

:   Tenascin-C

TNFα

:   Tumor Necrosis Factor alpha.
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